Atopic dermatitis: a review of topical treatment options
- 13 January 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 26 (3), 633-640
- https://doi.org/10.1185/03007990903512156
Abstract
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with a wide range of severity, and is usually the first manifestation of atopic disease. It is one of the most common skin disorders in developed countries, affecting approximately 20% of children and 1–3% of adults. Symptoms such as eczematous papules, plaques, and itch, and their associated consequences, such as sleep disturbance, can significantly impact the quality of life of the patient and family. This is a broad-based review focusing on clinical practice for primary care physicians treating patients with AD. The PubMed database was searched (to 1 November 2008) for English-language articles containing the keywords atopic dermatitis, atopic eczema, topical calcineurin inhibitor, tacrolimus, pimecrolimus, or corticosteroid. Articles focusing on clinical practice for patients with AD were chosen for further review. A limitation is that this is not a systematic review of the literature. Emollients have long been used to maintain the skin barrier function in patients with AD. Topical corticosteroids have been the pillar of medicated therapy for AD since their introduction nearly 50 years ago. The introduction of topical calcineurin inhibitors more than 8 years ago represented the first new class of medication approved for the treatment of AD since topical corticosteroids. Topical calcineurin inhibitors provide targeted anti-inflammatory activity without the local or systemic side-effects seen with topical corticosteroids. More recently, three new, nonsteroidal, barrier creams (Atopiclair , Mimyx , and Epiceram ) have entered the marketplace for AD treatment. A multi-therapeutic approach that incorporates short-term management of flares and longer-term strategies to prolong the time between flares is needed for the treatment of AD. Multiple topical therapies have been successfully used to treat patients with AD. An understanding of the available treatment options will help primary care providers striving to achieve best practice in the management of AD.Keywords
This publication has 42 references indexed in Scilit:
- Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative studyPediatric Allergy and Immunology, 2008
- Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areasCurrent Medical Research and Opinion, 2008
- Atopic and non-atopic eczemaBMJ, 2006
- MimyX CreamSKINmed: Dermatology for the Clinician, 2006
- Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studiesJournal of the American Academy of Dermatology, 2005
- Guidelines of care for atopic dermatitisJournal of the American Academy of Dermatology, 2004
- Consensus conference on pediatric atopic dermatitisJournal of the American Academy of Dermatology, 2003
- Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group studyBMJ, 2003
- Clinical aspects, epidemiology, and prognosis of atopic dermatitisAnnals of Allergy, Asthma & Immunology, 1999